Topics

. He can be reached at nsaraceno@mjhlifesciences.com.

Videos

In the first part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, discusses both the successes and challenges in commercializing cell and gene therapies.

Preparing for CGT Launches

Articles

The report spotlights China’s rapid biopharma advancement, alongside a GLP-1 surge, caution surrounding M&A, and a rise in biologics.

Evaluate Issues Annual World Preview Report

In the third part of her Pharma Commerce video interview, LeAnn Boyd, Liviniti’s founder and CEO, explains how a flat admin fee model can potentially create more value for both payers and patients.

Establishing Additional Transparency

The 200,000 square-foot Madison, WI facility will serve as the flagship location, with capabilities for future growth. 

TekniPlex Healthcare Unveils New Barrier Protection Systems Plant

Though this specific agreement centers around aerospace and automobiles, the greater supply chain will wait and see how Trump’s import taxes impact pharmaceuticals, a sector that faces a potential 25% tax on imports.

United States, United Kingdom Reach Tariff-Lowering Deal

The biopharma company—whose US headquarters is in Atlanta—will be building a new biologics manufacturing facility in a city to be named at a later date. 

UCB to Invest $5 Billion into US Production Plant

The acquisition of Cryoport’s specialty courier business is now finalized, with a value of approximately $200 million. 

DHL Officially Obtains CRYOPDP

In order to succeed in today’s outcomes-driven healthcare landscape, pharmaceutical companies must move from traditional sales models to strategic, measurable partnerships with integrated delivery networks (IDNs).

Bridging the Gap Between Strategy and Practice in IDN Partnerships

Marketed as BNT327, the PD-L1xVEGF-A bispecific antibody has the potential to become what the involved parties believe is a ‘foundational immuno-oncology backbone.’

BioNTech, BMS to Co-Design and Co-Commercialize New Antibody Candidate for Various Types of Tumors

Potential import taxes on pharma goods entering the United States continue to have effects on the industry in more ways than one. 

Business and Finance